12:00 AM
 | 
Jun 15, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AT-101: Phase II data

In an open-label Phase II trial in 23 treatment-naïve patients, AT-101 plus rituximab produced a response rate of 26% at week 8, which did not meet criteria to enroll the planned 52 patients. Grade 3/4 adverse events included nausea (17%), vomiting (9%), abdominal...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >